Tocilizumab for neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease refractory or intolerant to previous lines of therapy

Document first published:: 31 July 2025
Page updated:: 31 July 2025
Topic:: Specialised commissioning
Publication type:: Policy or strategy

NHS England will commission tocilizumab for neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) refractory or intolerant to previous lines of therapy (adults) in accordance with the criteria outlined in this policy.

Document

$Clinical commissioning policy: Tocilizumab for neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) refractory or intolerant to previous lines of therapy (Adults)$

Clinical commissioning policy: Tocilizumab for neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) refractory or intolerant to previous lines of therapy (Adults)

PDF
402 KB

Document

$Clinical panel report: Tocilizumab for neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) refractory or intolerant to previous lines of therapy (Adults)$

Clinical panel report: Tocilizumab for neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) refractory or intolerant to previous lines of therapy (Adults)

PDF
162 KB

Document

$Equality and health inequalities impact assessment: Tocilizumab for neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) refractory or intolerant to previous lines of therapy (Adults)$

Equality and health inequalities impact assessment: Tocilizumab for neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) refractory or intolerant to previous lines of therapy (Adults)

PDF
216 KB

Document

$CPAG summary report: Tocilizumab for neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) refractory or intolerant to previous lines of therapy (Adults)$

CPAG summary report: Tocilizumab for neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) refractory or intolerant to previous lines of therapy (Adults)

PDF
269 KB

Document

$Evidence review: Tocilizumab for neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) refractory or intolerant to previous lines of therapy (Adults)$

Evidence review: Tocilizumab for neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) refractory or intolerant to previous lines of therapy (Adults)

PDF
846 KB

Document

$Stakeholder engagement report: Tocilizumab for neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) refractory or intolerant to previous lines of therapy (Adults)$

Stakeholder engagement report: Tocilizumab for neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) refractory or intolerant to previous lines of therapy (Adults)

PDF
185 KB

Cookies on the NHS England website

Clinical commissioning policy: Tocilizumab for neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) refractory or intolerant to previous lines of therapy (Adults)

Clinical panel report: Tocilizumab for neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) refractory or intolerant to previous lines of therapy (Adults)

Equality and health inequalities impact assessment: Tocilizumab for neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) refractory or intolerant to previous lines of therapy (Adults)

CPAG summary report: Tocilizumab for neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) refractory or intolerant to previous lines of therapy (Adults)

Evidence review: Tocilizumab for neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) refractory or intolerant to previous lines of therapy (Adults)

Stakeholder engagement report: Tocilizumab for neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) refractory or intolerant to previous lines of therapy (Adults)